This article highlights the ongoing debate on the ethics and accessibility of cell and gene therapies, particularly for treating rare diseases. While these therapies can offer lifesaving benefits, many patients lack access due to factors like cost and distribution. The industry grapples with ethical dilemmas such as how to balance innovation and accessibility, and how to democratize access to critical treatments.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
